Tenecteplase (TNK) vs alteplase (tPA) thrombolysis for acute ischemic stroke — mechanism, dosing, efficacy, safety, and workflow
Alteplase (recombinant tissue plasminogen activator, rt-PA) has been the standard thrombolytic for acute ischemic stroke since the NINDS trial (1995). Tenecteplase is not a different drug class — it is alteplase itself, re-engineered at three sites to slow clearance, resist its natural inhibitor, and concentrate its enzymatic activity on fibrin rather than free-floating plasminogen. The result is a molecule with a longer half-life and sharper clot selectivity, administered as a single bolus rather than a prolonged infusion.
Tenecteplase is produced by site-directed mutagenesis of the native tPA gene, introducing three engineered changes:
• T103N (finger domain): adds a glycosylation site that reduces plasma clearance by hepatic receptors, extending circulating half-life roughly four- to five-fold.
• N117Q (kringle-1 domain): removes an existing glycosylation site, further reducing clearance and slightly altering fibrin-binding kinetics.
• KHRR296-299→AAAA (protease domain): replaces four residues in a loop that normally allows PAI-1 (plasminogen activator inhibitor-1) to bind and neutralize tPA. This substitution makes TNK roughly 80-fold more resistant to PAI-1 inactivation while sharply increasing its fibrin specificity — the enzyme becomes far more dependent on fibrin as a cofactor to efficiently activate plasminogen.
The combined effect: TNK stays active in circulation longer, resists the body's own shutoff mechanism, and concentrates plasmin generation at the clot surface rather than diffusely — a molecular rationale for both its single-bolus dosing and its comparable-or-better safety profile despite a longer half-life.
Because TNK is 14× more fibrin-specific than alteplase, plasminogen activation is concentrated where fibrin is present — on the thrombus surface — rather than throughout the systemic circulation, which is the pharmacological basis for administering it as one bolus instead of a titrated hour-long infusion.
Both drugs are serine proteases that catalyze the same core reaction: cleavage of the zymogen plasminogen into active plasmin. Plasmin then degrades the fibrin mesh that gives a thrombus its structural integrity, splitting it into soluble fibrin degradation products and restoring luminal blood flow.
Both alteplase and tenecteplase are fibrin-dependent enzymes — fibrin acts as a cofactor that dramatically increases their catalytic efficiency for plasminogen (up to several hundred-fold acceleration when fibrin is present versus free solution). TNK's protease-domain mutation amplifies this dependency, making it comparatively even less active against circulating plasminogen in the absence of fibrin — theoretically reducing "off-target" systemic fibrinogen depletion, though clinically the two drugs still produce broadly similar changes in fibrinogen levels at therapeutic doses.
The clinical practicality gap between these two thrombolytics is enormous even though their molecular mechanism is nearly identical. Alteplase requires weight-based dosing split into a bolus and a continuous infusion monitored for a full hour; tenecteplase requires one weight-based calculation and a single push. This difference dominates real-world stroke-code logistics far more than any subtle efficacy signal.
Standard alteplase dosing for acute ischemic stroke: total dose 0.9 mg/kg, capped at 90 mg for patients ≥100 kg.
• 10% of the total dose is given as an IV bolus over ~1 minute. • The remaining 90% is infused continuously over the following 60 minutes via a dedicated infusion pump. • The infusion line must be monitored for the full hour: pump malfunction, line occlusion, or a patient transfer mid-infusion can interrupt dosing and complicate the neurological exam (which must also be tracked closely during this window for signs of hemorrhagic conversion). • If the patient needs to be moved — for a CT scan, to a procedure suite, or via interhospital transfer to a thrombectomy center — a pump and trained staff must accompany them for the remainder of the infusion.
Tenecteplase dosing: 0.25 mg/kg, capped at 50 mg, given as a single intravenous bolus over approximately 5 seconds.
• No infusion pump, no hour of line monitoring, no risk of infusion interruption. • The full pharmacologic dose is committed at the moment of injection — the clinical team can immediately move to the next step (transport, thrombectomy work-up, ward transfer) without being tethered to a pump. • Pharmacy preparation is also simpler: TNK is reconstituted as a fixed-concentration solution and drawn up according to weight-based volume, reducing programming steps compared to calculating and setting an infusion pump rate.
This simplicity is not merely a convenience — in emergency neurology, every step that can fail (a kinked line, a pump alarm, a delayed restart after moving the patient) is a step that can delay reperfusion, and time lost is brain tissue lost ("time is brain").
A useful way to frame it clinically: alteplase asks the team to manage a 61-minute process under time pressure, while tenecteplase asks for one correct weight-based calculation executed once. Fewer steps mean fewer opportunities for dosing error or delay during the highest-acuity phase of stroke care.
A decade of head-to-head and registry data — NOR-TEST, ATTEST, EXTEND-IA TNK, EXTEND-IA TNK Part 2, and the large pragmatic AcT trial (Lancet, 2022) — has progressively shifted stroke guidelines toward tenecteplase, driven largely by evidence that it achieves comparable or better early reperfusion, particularly in patients bridging to mechanical thrombectomy for large-vessel occlusion (LVO).
• NOR-TEST (2017): first large randomized trial of TNK 0.4 mg/kg vs alteplase in a broad stroke population — similar functional outcomes and safety, though this higher off-label dose is not the one now used clinically.
• EXTEND-IA TNK (2018, NEJM): in patients with LVO planned for thrombectomy, TNK 0.25 mg/kg achieved substantial reperfusion (>50% of the affected territory) before the thrombectomy procedure in 22% of patients vs 10% for alteplase — meaning more clots were already dissolving by the time the interventionalist began the procedure.
• ATTEST-2, EXTEND-IA TNK Part 2, and multiple national registries reinforced that TNK 0.25 mg/kg is non-inferior to alteplase for 90-day functional outcome across broader stroke populations, including patients not going to thrombectomy.
• AcT trial (2022, Lancet): a large pragmatic Canadian trial (n=1577) confirmed non-inferiority for the primary outcome (modified Rankin Scale 0–1 at 90 days) in routine clinical practice, supporting a shift to TNK as a default agent in many stroke networks.
For LVO stroke, IV thrombolysis is typically given as a "bridging" therapy before mechanical thrombectomy, not as a replacement for it. The clinical value of the thrombolytic in this setting is partly measured by how much clot dissolves in the window between the IV bolus/infusion and the start of the endovascular procedure.
Because TNK's full dose is committed within seconds and it is highly fibrin-specific, plasmin generation at the clot surface can begin promptly and continue uninterrupted while the patient is being transported to the angiography suite — whereas alteplase's effective dose is still being delivered for up to an hour, some of which may occur after the procedure has already started or during transport with a running pump.
Higher rates of substantial reperfusion before the catheter even reaches the clot translate into shorter procedure times, sometimes obviate the need for thrombectomy altogether in a subset of patients, and are associated with better downstream functional outcomes.
EXTEND-IA TNK found reperfusion of more than half the affected vascular territory before thrombectomy began in roughly 1 in 5 tenecteplase patients versus 1 in 10 alteplase patients — a difference plausibly explained by TNK's rapid full-dose delivery and higher fibrin specificity rather than any difference in the underlying catalytic mechanism.
The central safety concern for any thrombolytic in stroke is symptomatic intracranial hemorrhage (sICH) — bleeding into brain tissue that causes clinical worsening. Despite tenecteplase's longer half-life and greater resistance to its natural inhibitor, randomized and pragmatic trials have consistently found sICH rates statistically comparable to alteplase at the approved 0.25 mg/kg dose.
It might seem counterintuitive that a longer-acting, PAI-1-resistant thrombolytic would not carry higher hemorrhage risk. The explanation lies in TNK's fibrin selectivity: because its catalytic efficiency depends heavily on binding fibrin, it is comparatively less active against plasminogen circulating freely in blood without a fibrin cofactor. This limits indiscriminate systemic plasmin generation and the associated depletion of clotting factors like fibrinogen and factor V/VIII, which is one mechanism behind thrombolytic-related bleeding.
At the approved stroke dose (0.25 mg/kg, capped 50 mg) — lower relative to body weight than the earlier 0.4 mg/kg dose tested in NOR-TEST — the pharmacodynamic balance nets out to a bleeding risk indistinguishable from alteplase across the major trials, while still retaining the reperfusion advantages described in Stage 3.
Meta-analyses pooling AcT, EXTEND-IA TNK, NOR-TEST 2, and other randomized comparisons consistently report:
• Symptomatic ICH: no statistically significant difference between TNK 0.25 mg/kg and alteplase 0.9 mg/kg, with point estimates for both agents in the low single digits (definitions vary by trial — ECASS-III vs SITS-MOST vs NINDS criteria — which affects exact percentages reported).
• Any intracranial hemorrhage (including asymptomatic): also broadly similar, though some individual studies show numerically fewer any-ICH events with TNK, without reaching statistical significance.
• 90-day mortality and major systemic bleeding: no consistent signal of excess risk with tenecteplase.
The consistency of this safety finding across trial designs, dosing eras, and populations (including LVO patients bridging to thrombectomy) is a major reason multiple national and international stroke guidelines now list tenecteplase as an acceptable, and in some networks preferred, alternative to alteplase.
Clinical takeaway: at the guideline-recommended 0.25 mg/kg dose, tenecteplase does not trade safety for convenience. The workflow and reperfusion advantages described elsewhere in this comparator come without a measurable increase in symptomatic hemorrhage risk.
Beyond molecular pharmacology and trial endpoints, tenecteplase's biggest real-world impact may be operational: removing the hour-long infusion collapses a fragile, multi-step process into a single action, which measurably shortens door-to-needle time and simplifies the increasingly common "drip-and-ship" model of stroke care, in which a patient is thrombolysed at a local hospital and transferred to a comprehensive stroke center for thrombectomy.
A typical stroke code proceeds: patient arrival → rapid triage and NIH Stroke Scale → non-contrast CT/CTA → decision for thrombolysis → weight-based dose calculation → pharmacy preparation → administration → ongoing neuro checks → decision on thrombectomy/transfer.
With alteplase, the "administration" step alone occupies up to an hour, and the "ongoing neuro checks" step must track a pump that could fail, be programmed incorrectly, or require restart after a step such as a repeat CT. Nursing and pharmacy staff must coordinate the second infusion bag change and confirm exact volumes.
With tenecteplase, dose calculation and preparation are still required, but administration itself is a single push — the care team can move immediately to the next workflow step (repeat imaging, transfer coordination, thrombectomy prep) without a pump tethering the patient to a specific room or ambulance configuration.
Many patients present to smaller hospitals without on-site thrombectomy capability and must be transferred to a comprehensive stroke center. Under a drip-and-ship alteplase protocol, the ambulance or helicopter transport team must manage a running infusion pump, monitor the line, and be prepared to troubleshoot pump alarms mid-transport — adding clinical risk and logistical complexity to an already time-critical transfer.
With tenecteplase, the full therapeutic dose is administered before the patient ever leaves the referring hospital. Transport teams do not need to manage an infusion device, reducing equipment requirements, staff training burden, and the chance of a dosing interruption during transit. Several stroke networks that have switched to tenecteplase as their default thrombolytic report measurable reductions in door-to-needle time and smoother interfacility transfer logistics, reinforcing why society guidelines increasingly frame TNK as a reasonable — and operationally favorable — alternative to alteplase.
The workflow case for tenecteplase is additive to, not separate from, its clinical case: faster, simpler administration shortens the time to reperfusion-relevant treatment, which is itself the mechanism by which stroke thrombolysis improves outcomes. In time-critical neurology, logistics and pharmacology point in the same direction.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Dose | |||
| Administration | |||
| Fibrin specificity | |||
| Symptomatic ICH | |||
| Transfer logistics |